Celltrion, Inc., a biopharmaceutical manufacturer, opened a Global R&D Center in South Korea to support breakthrough therapies. The company is expanding its presence in the U.S. market, and has recently obtained breakthroughs for its efforts to make its treatments accessible to American patients with the July 2023 launch of its Humira biosimilar, Yuflyma and FDA application for a novel subcutaneous formulation of infliximab. The center is a state-of-the-art R&D hub for developing next...